Form 4: Jasper Therapeutics COO Jeetinder Singh Mahal Executes Stock Option and Sells Shares Under 10b5-1 Plan

Jeetinder Singh Mahal, COO of Jasper Therapeutics, exercised stock options and sold 900 shares of voting common stock at an average price of $26.4358, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On March 12, 2024, Jeetinder Singh Mahal, the Chief Operating Officer of Jasper Therapeutics, exercised a stock option to acquire 900 shares of voting common stock at a price of $7.10.
• Simultaneously, Mahal sold 900 shares of voting common stock at a weighted average price of $26.4358, with individual sales prices ranging from $26.14 to $26.79.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mahal on March 15, 2023.
• Following these transactions, Mahal directly owns 25,009 shares of Jasper Therapeutics voting common stock and holds options for 16,472 shares.
• The reported share numbers and option exercise price reflect adjustments due to a 1-for-10 reverse stock split effective January 4, 2024.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The use of a 10b5-1 plan suggests pre-planned transactions, reducing the likelihood of a significant negative impact. The reverse stock split is a known event.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The reverse stock split is a corporate action often undertaken to increase the stock price to meet listing requirements or attract institutional investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• The disclosure provides transparency regarding insider trading activities.

Key Dates